Protein Kinase Inhibitors: all 15,766 studies that test it
Page 22 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.
- SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT05445154Phase 1/2
- Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular CarcinomaRecruitingNCT05444478Not applicable
- A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered MalignanciesRecruitingNCT05443126Phase 1/2
- A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC PatientsEnrolling by invitationNCT05441475Phase 2
- Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ CarcinomaRecruitingNCT05439993Phase 1/2
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingNCT05436418Phase 1/2
- Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung CancerRecruitingNCT05435274Phase 1/2
- Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)RecruitingNCT05435248Phase 1/2
- Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
- The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
- Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer PatientsNot yet recruitingNCT05426811Phase 1/2
- Thal-Fabs: Reduced Toxicity Conditioning for High Risk ThalassemiaRecruitingNCT05426252Phase 1/2
- Cabozantinib for Patients With Recurrent or Progressive MeningiomaRecruitingNCT05425004Phase 2
- Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)RecruitingNCT05414292Not applicable
- mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCRecruitingNCT05412589Phase 2
- Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)RecruitingNCT05410197Phase 2
- the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaRecruitingNCT05408221Phase 2/3
- A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionRecruitingNCT05407519Phase 2
- Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerRecruitingNCT05401110Phase 1
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingNCT05398809Phase 2
- A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLCRecruitingNCT05394831Phase 1/2
- BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT05393466Phase 1/2
- Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
- A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular LymphomaRecruitingNCT05389293Phase 2
- Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual DiseaseRecruitingNCT05388149Phase 2
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskRecruitingNCT05385549Phase 2
- Axitinib and Nivolumab for the Treatment of Mucosal MelanomaRecruitingNCT05384496Phase 2
- Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA TrialRecruitingNCT05382741Phase 2
- Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)RecruitingNCT05382728Phase 3
- NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsRecruitingNCT05382377Early Phase 1
- Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingNCT05381506Phase 2
- High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) MetastasesRecruitingNCT05379803Phase 2
- Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsRecruitingNCT05372640Phase 1
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingNCT05372614Phase 1
- Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune ThrombocytopeniaNot yet recruitingNCT05369377Phase 2
- The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune ThrombocytopeniaNot yet recruitingNCT05369364Phase 2
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruitingNCT05367765Phase 4
- A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.RecruitingNCT05367700Phase 1
- A Study of ICP-033 in Patients With Advanced Solid TumorsRecruitingNCT05367232Phase 1
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingNCT05366816Phase 2
- Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More TreatmentRecruitingNCT05363280Phase 2
- Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingNCT05362760Phase 4
- Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2
- A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and LymphomaRecruitingNCT05358379Phase 1/2
- A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT05353205Phase 4
- Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
- WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLCRecruitingNCT05351320Phase 2
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyRecruitingNCT05342194Phase 3
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingNCT05341583Phase 3
- Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT05338931Phase 1/2
- A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyRecruitingNCT05338619Phase 2
- Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
- Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System LymphomaRecruitingNCT05334238Phase 3
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasRecruitingNCT05331105Phase 2
- Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform HemangioendotheliomaRecruitingNCT05324384Phase 2
- Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell CancerNot yet recruitingNCT05322499Phase 2
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)RecruitingNCT05319353Phase 3
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingNCT05313958Phase 2/3
- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)RecruitingNCT05308264Phase 1/2
- Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067RecruitingNCT05306132Phase 1
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingNCT05306041Phase 2
- Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerRecruitingNCT05305924Phase 2
- Stand UP to Rheumatoid Arthritis (SUPRA)RecruitingNCT05305066Not applicable
- FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast CancerRecruitingNCT05304962Phase 1
- A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid LeukemiaRecruitingNCT05304377Phase 1
- Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung CancerRecruitingNCT05296603Phase 2
- Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast CancerRecruitingNCT05296577Phase 2
- Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerRecruitingNCT05292742Phase 2
- ZR-CHOP in DLBCL With Specific Gene AbnormalityRecruitingNCT05290337Phase 2
- ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLRecruitingNCT05290090Phase 2
- MEKTOVI® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaRecruitingNCT05286788Phase 2
- Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.Not yet recruitingNCT05286320Phase 1/2
- Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor TherapyRecruitingNCT05283226Phase 2
- Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)RecruitingNCT05281406Phase 2
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibRecruitingNCT05280509Phase 1/2
- Descemet Endothelial Thickness Comparison Trial IIRecruitingNCT05275972Phase 3
- XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNot yet recruitingNCT05275374Phase 1/2
- First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsRecruitingNCT05271916Phase 1/2
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.RecruitingNCT05271292Phase 1/2
- Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid TumorsRecruitingNCT05269316Phase 1/2
- Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung CancerRecruitingNCT05267288Phase 2
- HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K MutationRecruitingNCT05263453Phase 2
- To Evaluate KC1036 in the Patients with Advanced Digestive System TumorsRecruitingNCT05260385Phase 1/2
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaRecruitingNCT05256641Phase 1/2
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingNCT05253651Phase 3
- Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT05252078Phase 2
- TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCRecruitingNCT05250843Phase 2/3
- SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsRecruitingNCT05245058Early Phase 1
- Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied PatientsNot yet recruitingNCT05241561Phase 2
- Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerRecruitingNCT05241028Phase 2
- Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCLNot yet recruitingNCT05238064Phase 1/2
- The Role of Sirolimus in Preventing Functional Decline in Older AdultsRecruitingNCT05237687Phase 2
- A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric CancerRecruitingNCT05235906Phase 2
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaRecruitingNCT05234684Phase 3
- mTOR as Mediator of Insulin Sensitivity StudyRecruitingNCT05233722Not applicable